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Abstract
Head and neck squamous cell carcinomas (HNSCC)
constitute a majority of the tumors of the upper aero-
digestive tract and continue to present a significant
therapeutic challenge. To explore the potential of
vascular-targeted therapy in HNSCC, we investigated
the antivascular, antitumor activity of the potent
vascular-disrupting agent (VDA) 5,6-dimethylxan-
thenone-4-acetic acid (DMXAA) against two HNSCC
xenografts with markedly different morphologic and
vascular characteristics. Athymic nude mice bearing
subcutaneous FaDu (human pharyngeal squamous cell
carcinoma) and A253 (human submaxillary gland epi-
dermoid carcinoma) tumors were administered a single
dose of DMXAA (30 mg/kg, i.p). Changes in vascular
function were evaluated 24 hours after treatment using
contrast-enhanced magnetic resonance imaging (MRI)
and immunohistochemistry (CD31). Signal enhance-
ment (E ) and change in longitudinal relaxation rates
(#R1) were calculated tomeasure alterations in vascular
perfusion. MRI showed a 78% and 49% reduction in
vascular perfusion in FaDu and A253 xenografts,
respectively. CD31-immunostaining of tumor sections
revealed three-fold (FaDu) and two-fold (A253) reduc-
tions in microvessel density (MVD) 24 hours after
treatment. DMXAA was equally effective against both
xenografts, with significant tumor growth inhibition
observed 30 days after treatment. These results indicate
that DMXAA may be beneficial in the management of
HNSCC, alone or in combination with other treatments.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) repre-
sent more than 90% of all head and neck cancers, with
f37,000 new cases reported annually in the United States
[1,2]. A majority of the patients with early-stage disease are
treated with either surgery or radiation [3]. Management of
patients with locoregional advanced disease typically includes
the use of cytotoxic chemotherapeutic agents [3,4]. However,
clinical response rates of HNSCC have remained relatively
unchanged over the years, especially in patients with re-
current or metastatic disease, highlighting the need for a multi-
disciplinary therapeutic approach [3,4]. Clinical studies have
often focused on improving antitumor activity by combining
therapies that target multiple tumor pathways [5]. Recent ran-
domized clinical trials have also demonstrated increased re-
sponse rates with combination strategies compared to those
with single-agent therapies [5,6].
To grow, solid tumors need nutrients and oxygen supplied by
blood vessels [7]. As such, selective targeting of established
tumor vasculature represents an attractive anticancer strategy
[8], and a number of vascular-disrupting agents (VDAs) are
being actively pursued in research and clinical settings [9]. 5,6-
Dimethylxanthenone-4-acetic acid (DMXAA) is one such potent
VDA that has been shown to possess excellent antitumor ac-
tivity against transplanted murine tumors [10,11] and xeno-
grafts [11–15]. Biologic response to DMXAA is a result of
direct drug effects on endothelial cells and of indirect effects
mediated by cytokines such as tumor necrosis factor a [16].
Vascular effects of DMXAA are usually seen within a few hours
after administration and include changes in vascular perme-
ability that lead to plasma loss, increased blood viscosity, intra-
vascular thrombosis, and eventual loss of blood flow within
the tumor [16]. Several studies have reported the effects of
DMXAA in human tumor xenograft models, including mela-
nomas [11], colorectal cancer [12], ovarian cancer [11,13],
breast cancer [13], prostate cancer [14], and lung cancer [15].
However, the antitumor activity of DMXAA against HNSCC
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has not been previously investigated.We therefore evaluated
the antivascular and antitumor effects of DMXAA using two
HNSCCxenografts, FaDu (human pharyngeal squamous cell
carcinoma) and A253 (human submaxillary gland epidermoid
carcinoma), that have been previously shown to vary in
morphologic characteristics, vascularity, and response to
irinotecan therapy [17]. The objectives of the study were to
determine if: 1) the vascular responses of the two xenografts
to DMXAA were different; 2) long-term tumor response rates
were different; and 3) the observed early alterations in
vascular function were predictive of treatment outcome.
The effects of DMXAA on tumor vasculature were evaluated
using noninvasive magnetic resonance imaging (MRI) and
immunohistochemical staining of tumor sections for the endo-
thelial cell adhesion molecule (CD31). Tumor response was
determined by monitoring tumor growth for a period of
30 days following treatment.
Materials and Methods
HNSCC Xenografts
The human head and neck carcinoma lines FaDu [18] and
A253 [19] were originally purchased from the American Type
Culture Collection (Manassas, VA). The xenografts were
initially established by subcutaneously injecting 106 cells into
athymic nude mice. For experiments, visibly non-necrotic
tumor pieces obtained from donor mice were transplanted
into the flanks of 12-week-old female athymic nude mice
(nu/nu; Harlan Sprague Dawley, Inc., Indianapolis, IN), as
described previously [20]. Studies were performed when
tumors were approximately 5 to 7 mm in diameter.
DMXAA
Solid DMXAA (courtesy of Gordon Rewcastle, University
of Auckland, Auckland, New Zealand) was stored at room
temperature in the dark and dissolved in 0.5% sodium
bicarbonate immediately before intraperitoneal injection at a
dose of 30 mg/kg.
MR Contrast-Enhancing Agent
Albumin-GdDTPA [21] (courtesy of Robert Brasch) was
obtained from Contrast Media Laboratory, Department of
Radiology, University of California at SanFrancisco (SanFran-
cisco, CA). This agent has been extensively characterized
and used for experimental studies [22,23]. The agent con-
tains 35GdDTPAmolecules (94.3mM) that are bound to each
human serum albumin (2.69 mM). T1 relaxivity was calculated
to be 11.3 mM1 sec1 per Gd ion at 25jC and 10 MHz.
Contrast-Enhanced MRI
Mice were imaged using a 4.7-T/33-cm horizontal bore
magnet (GE NMR Instruments, Fremont, CA) incorporating
AVANCE digital electronics [Bruker Biospec, ParaVision 3.0.2
(OS); Bruker Medical, Billerica, MA], a removable gradient coil
insert (G060; Bruker Medical) generating a maximum field
strength of 950 mT/m, and a custom-designed radiofrequency
transreceiver coil. Animals were anesthetized before imag-
ing with a ketamine/xylazinemixture (10:1) at a dose of 1.0 ml/
100 mg, secured in a mouse coil chamber, and positioned on
a scanner. The animals were kept warm in the magnet using
a circulating water bath maintained at 37jC. Data acquisi-
tion consisted of a localizer, T1-weighted MR images, and
T2-weighted MR images. Anatomic coverage included the
tumor, kidneys, and muscles. In addition, a signal-to-noise
calibration standard (phantom containing a known concentra-
tion of contrast agent) was placed in the field of view (FOV) to
normalize signal intensity (SI) values obtained from different
animals over time. A series of three preliminary noncontrast-
enhanced images, with repetition times (TR) ranging from 360
to 6000 milliseconds, was acquired before an intravenous
bolus injection of the contrast agent for the determination of
regional precontrast T1 relaxation values. Following these
baseline acquisitions, albumin-GdDTPA (0.1 mmol/kg) was
introduced manually through tail vein injection, and a second
series of five postcontrast images was serially obtained for
f45 minutes (day 1), as described previously [22,23]. T1 re-
laxation rates were determined using a saturation recovery,
fast spin echo sequence with an effective echo time (TE) of
10 milliseconds, and a TR ranging from 360 to 6000 milli-
seconds [FOV= 32 32mm, slice thickness = 1.0mm,matrix
size = 128  96 pixels, number of excitations (NEX) = 3]. Fol-
lowing image acquisition, animals were allowed to recover,
and 30 mg/kg DMXAA was injected intraperitoneally in a
volume of 0.2 ml of 0.5% sodium bicarbonate in distilled water.
Twenty-four hours after DMXAA administration, a second set
of images was acquired with an identical imaging protocol as
that on day 1. The mice then received a second injection of
albumin-GdDTPA at the same dose, and imaging was per-
formed for f45 minutes after contrast agent administration,
as before. On completion of image acquisitions, mice were
humanely sacrificed, and tumors were excised for immuno-
histochemistry and histology. All procedures were carried out
in accordance with protocols approved by the RPCI Institu-
tional Animal Care and Use Committee.
Image Processing and Data Analysis
Image processing and analysis were carried out using
commercially available software (ANALYZE PC, Version 5.0;
Biomedical ImagingResource,Mayo Foundation, Rochester,
MN) (Matlab’s curve-fitting toolbox, Matlab Version 7.0; Math
Works, Inc., Natick, MA) and source codes developed by the
RPCI Preclinical Imaging Resource. Regions of interest
(ROI) of tumors, kidneys, and muscle tissues were manually
drawn in the images and object maps of the ROI constructed.
SI values from different ROI were obtained and used to
calculate tumor enhancement (E ) [22,23]. SI values were
corrected for temporal variation in the spectrometer by nor-
malizing to the phantom. Percent tumor enhancement (E )
was then calculated from relative intensity (RI)
RI ¼ SItumor=SIphantom
in precontrast and postcontrast images and reported as
percent enhancement using the formula
E ¼ ½ðRIpost  RIpreÞ=RIpre  100%
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Tumor T1 relaxation rates (R1 = 1 / T1) were calculated
from serially acquired images obtained before and after the
administration of albumin-GdDTPA. Precontrast and post-
contrast R1 values were calculated as previously described
[24]. To calculate DMXAA-induced changes in vascular vol-
ume and permeability, the change in longitudinal relaxation
rate DR1 was calculated over time by subtracting the average
precontrast R1 value from each of the five serially acquired
postcontrastR1measurements.DR1 values were reported as
a function of time before and after DMXAA treatment. The
slope of the DR1 series was used as a measure of vascular
permeability, and Y-intercept was used to estimate vascular
volume, similar to the method described previously by
Bhujwalla et al. [25].
Immunohistochemical Analysis of Microvessel
Density (MVD)
Tumors were excised and immediately placed in Tris-
buffered zinc fixative (BD Biosciences Pharmingen, San
Diego, CA) overnight, transferred to 70% ethanol, dehy-
drated, and embedded in paraffin. Sections 5 mm thick were
stained after conventional deparaffinization, endogenous
peroxidase quenching with 3% H2O2, and pretreatment
with 0.03% casein in phosphate-buffered saline (PBS) with
500 ml/l Tween for 30 minutes at room temperature to block
unspecific binding. Slides were counterstained with Harris
hematoxylin (Poly Scientific, Bayshore, NY). Mouse CD31
was detected with rat monoclonal antibody (IgG2a; BD Bio-
sciences Pharmingen) at 1:50 dilution in PBS for 60 minutes
at 37jC. This was followed by the addition of biotinylated
rabbit anti-rat IgG (12112D; Biosciences Pharmingen) at
1:100 dilution for 30 minutes, streptavidin peroxidase
(50-242; Zymed, San Francisco, CA) for 30 minutes, and di-
aminobenzidine for 5 minutes [17,26]. An isotype-matched
control (10 mg/ml rat IgG) was used on a duplicate slide in
place of the primary antibody as a negative control. Intra-
tumoral blood vessels were counted on cross sections of
whole tumor under the high-power field (HPF) of a light
microscope (original magnification, 400). Two to three sec-
tions from the center of each tumor were used to determine
the average number of microvessels per field. Vessels with a
clearly defined lumen or a well-defined linear vessel shape
were counted. Single endothelial cells were not counted
as vessels.
Tumor Response
Following treatment, tumors were measured with vernier
calipers every 1 to 3 days for a period of 30 days, and tumor
volumes were calculated using the formula 1 / 2(LW 2), where
L is the longest tumor axis. Actual tumor volume (ATV)
calculated on different days after treatment was normalized
to initial tumor volume (ITV) on the day of treatment and
was reported as: median tumor volume % [(ATV / ITV) 
100]. Tumor cure percentages are reported either as com-
plete response (CR) when no tumor was detected by palpa-
tion or as partial response (PR) when tumor volume was
temporarily reduced by 50% [17].
Statistics
All measured values are reported as mean ± standard
error of the mean. Three animals were used for MRI studies
for each tumor type. For immunohistochemistry, four to five
animals were used for control and DMXAA treatment groups.
Five to eight animals per group were used for tumor response
studies. Two-tailed t test and one-way analysis of variance
were used for comparing individual treatment groups with
controls. P = .05 was considered statistically significant. All
statistical calculations and analyses were performed using
Graph Pad Prism (Version 4.00; Graph Pad, San Diego, CA).
Results
Differences in Vascular Perfusion between Untreated FaDu
and A253 Xenografts
We have recently shown that A253 tumors consisted of
30% avascular regions and 70% poorly vascularized regions
(MVD = 10 per 400 HPF), whereas FaDu tumors had a
higher (MVD = 19 per 400) and more homogeneous dis-
tribution of microvessels [17]. Although both xenografts
responded to the chemotherapeutic agent irinotecan, the
greater resistance of A253 vs FaDu was attributed to inade-
quate drug uptake in the avascular and poorly vascularized
regions of A253 tumors.
To confirm these differences in tumor vasculature before
therapy with the antivascular and antitumor drug DMXAA,
percent enhancement (E) in MR signal intensity following
contrast agent administration was calculated in untreated
control tumors. As expected the enhancement values (indic-
ative of tumor tissue vascularity) were significantly different
(P < .05) between these tumors (Figure 1), with FaDu
xenografts exhibiting an approximately three-fold greater
enhancement than A253 tumors (82.04 ± 14.53 vs 27.24 ±
6.60, respectively). To further validate vascular differences
between the two xenografts, quantitative estimates of vascu-
lar perfusion were obtained from DR1 values calculated
following contrast agent administration. As seen in Figure 2,
a significant difference (P < .001) in DR1 was seen between
Figure 1. Vascular differences between FaDu and A253 xenografts. Graph
shows percent enhancement (E) in MR signal intensity following contrast
agent administration in FaDu and A253 human HNSCC implanted sub-
cutaneously in nude mice (two-tailed Student’s t test, *P < .05).
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untreated FaDu and A253 xenografts. These measured
differences in vascularity between FaDu and A253 are sum-
marized in Table 1.
Vascular Responses of FaDu and A253 Xenografts
to DMXAA
The vascular responses of FaDu and A253 xenografts
were studied using albumin-GdDTPA contrast-enhanced
MRI following administration of 30 mg/kg DMXAA. Change
in longitudinal relaxation rate (DR1) following contrast agent
administration was calculated 24 hours after DMXAA treat-
ment and was compared to pretreatment values. As seen
in Figure 2, there was a difference between the two xeno-
grafts in the degree of vascular response to DMXAA. Twenty-
four hours after treatment, FaDu tumors exhibited a 78%
reduction (P < .001) in DR1 (0.109 ± 0.005) compared to
baseline values (0.494 ± 0.053), indicative of a substantial
decrease in vascular perfusion. In contrast, A253 tumors
exhibited a 49% reduction (P < .01) in DR1 following DMXAA
(0.148 ± 0.012 and 0.076 ± 0.012) before and after treatment
respectively. To assess the effects of DMXAA on normal
tissue, DR1 values were calculated in the kidneys before
and after DMXAA treatment. As can be seen in Figure 2, no
significant change in DR1 was seen in the kidneys as a result
of DMXAA treatment. Additionally, no difference was seen
in R1 values calculated from a reference muscle tissue (data
not shown) before and 24 hours after DMXAA treatment.
To further characterize the differences in vascular re-
sponse between the two tumors, DR1 values were calculated
over time (f45 minutes) following contrast agent adminis-
tration. These DR1 values were then plotted as a function
of time, and parameters of vascular volume (Y-intercept) and
permeability (slope) were calculated. A linear increase inDR1
was seen in both FaDu and A253 tumors before treatment,
reflecting an accumulation of contrast agent (Figure 3). As
seen before, the vascular volume of control FaDu (0.297 ±
0.014) tumors was significantly higher (P < .0001) than
that of A253 tumors (0.102 ± 0.003) before DMXAA treat-
ment. Following DMXAA treatment, there was a highly sig-
nificant (P < .0001) three-fold reduction in the vascular
volume of FaDu tumors (Y-intercept = 0.090 ± 0.002), indica-
tive of significant DMXAA-induced vascular damage. Anal-
ysis of the two slopes also revealed significant differences
(P < .001), suggestive of alterations in permeability as a result
of impaired perfusion following DMXAA treatment. Analysis
of DR1 values of A253 tumors over time revealed a mod-
erate, but statistically insignificant, change (1.3-fold,P= .154)
in vascular volume following DMXAA treatment; there was a
small difference between the slopes of the DR1 value–time
plots, but it was not statistically significant (P = .143).
We then investigated if parameters of vascular function
determined by MRI correlated with histologic estimates of
MVD. To achieve this, immunohistochemical staining of
tumor sections was performed for the pan endothelial cell
adhesion molecule, CD31. Figure 4 shows histologic [hema-
toxylin and eosin (H&E)] and immunohistochemical (CD31)
sections of control and DMXAA-treated FaDu and A253
tumors. Histological section of untreated control FaDu tu-
mors showed uniformly poorly differentiated tumor cells
(panel A), with evenly distributed blood vessels as defined
by their positive CD31 immunoreactivity (panel B). Blood
vessels appeared as distinct clusters of endothelial cells with
intact lumen (arrows). Following DMXAA treatment, exten-
sive necrosis and hemorrhaging (panel C) were seen in FaDu
tumors, with marked loss of vessel integrity, a virtual ab-
sence of CD31 staining (panel D), and the presence of cel-
lular congestion inside vessel lumens (arrows). Control A253
tumors showed well-differentiated tumor regions (panel E )
with fewer blood vessels (panel F, arrows). DMXAA-treated
A253 tumor sections also showed necrosis and hemorrhage
(panel G), with considerable loss of CD31 immunostaining
and intravascular congestion (panel H, arrows).
MVD was calculated by an analysis of control and
DMXAA-treated tumor sections for CD31-positive blood
Figure 2. Vascular response of tumor and kidney tissues to DMXAA. Change
in T1 relaxation rates (DR1) of control and DMXAA-treated FaDu and A253
tumors calculated from serial T1-weighted MR images acquired before and
24 hours after administration of albumin-GdDTPA. The DR1 values of kidneys
before and 24 hours after DMXAA treatment are included. Values represent
mean ± SEM (two-tailed Student’s t test, ***P < .001, **P < .01, *P < .05).
Table 1. Summary of Histologic and Vascular Characteristics of Untreated HSNCC Xenografts and Tumor Response Rates Following a Single Treatment of
DMXAA.
Tumor Type Histologic Characteristics* MVDy % Enhancement (E )z DR1
z CR Rate (%)§
FaDu Uniformly poorly differentiated 20.75 ± 1.87 82.04 ± 14.53 0.494 ± 0.053 20
A253 30% Avascular and well-differentiated;
70% poorly differentiated
9.67 ± 1.33 27.24 ± 6.60 0.148 ± 0.012 20
*Bhattacharya et al. [17].
yImmunostaining of tumor sections with anti-CD31 antibody.
zContrast-enhanced MRI.
§Percent tumor-free mice.
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vessels in multiple HPFs (Figure 5). The results showed
that the MVDs of control FaDu and A253 tumors were con-
siderably different (P < .01), consistent with MR findings. A
significant decrease in MVD (P < .01 for FaDu and P < .05 for
A253) was seen in both tumor sections (Figure 5), in agree-
ment with MR findings.
To visualize the differences in vascular responses be-
tween FaDu and A253 xenografts, T1 relaxation maps
(Figure 6, maps B, D, F, and H ) were computed. Represen-
tative proton images are also shown (Figure 6, images A, C,
E, andG ). In the figure, images A, B,C, and Dwere obtained
before DMXAA treatment, and images E, F, G, and H were
acquired 24 hours after treatment. As seen in the figure,
before the DMXAA treatment, both tumors show increased
MR signal enhancement following contrast agent adminis-
tration (map D), with FaDu tumors (yellow arrows) exhibiting
greater enhancement than A253 tumors (white arrows).
Twenty-four hours after DMXAA treatment, no detectable
MR signal enhancement was seen in FaDu tumors following
contrast agent administration (map H ) compared to precon-
trast images (map F ). At the same time point, A253 showed
enhancement following treatment, indicating the presence of
functional vessels (maps F and H ).
Tumor Growth Inhibition of FaDu and A253 Xenografts
by DMXAA
We have shown that DMXAA reduced mean vessel den-
sity and vascular perfusion to different degrees in FaDu and
A253 xenografts. To test the effects of DMXAA on tumor
growth, tumor-bearing mice were injected with a single dose
(30 mg/kg) of DMXAA and monitored for a period of 30 days.
This treatment resulted in significant (P < .001) inhibition of
A253 and FaDu tumor growth relative to controls (Figure 7);
however, there was no difference in posttreatment growth
rates (P > .05) and cure rates (20%) between these two
tumor lines.
Discussion
Head and neck cancer is the fifth most common malignancy
worldwide and presents a significant challenge to clinicians
[1,2]. Standard treatment options, such as surgery, radiation,
or chemotherapy, or their combination, can result in tumor
cures and preservation of organs and function in early-
stage disease [3,4]. However, prognosis is poorer for patients
with advanced disease, indicating the need for new thera-
peutic approaches [4–6].
The critical role of the vasculature in tumor growth and
progression has generated a great deal of interest in drugs
that either disrupt existing tumor vessels or prevent new
vessel formation [7,8]. These vascular-targeted therapies
exploit differences in vascular physiology between normal
and tumor tissues [7,8]. Presently, a number of VDAs are
being evaluated against different types of cancers in pre-
clinical studies and on patients [9]. DMXAA is one such potent
VDA that has been shown to induce selective tumor vas-
cular shutdown and hemorrhagic necrosis in several murine
models and xenografts [10–15].We report here the response
of two HNSCC xenografts, FaDu and A253, to a single dose
of the VDA, DMXAA. Contrast-enhanced MRI and endo-
thelial cell immunostaining describe the loss of vascular in-
tegrity and function after DMXAA, which results in significant
inhibition of tumor growth 30 days after treatment.
In contrast to conventional anticancer therapies, VDAs
such as DMXAA are not expected to result in dramatic
changes in tumor size or volume [13,16]. In general, VDAs
are believed to be more effective against vessels in the in-
terior of the tumor, with a characteristic rim of cells in the
periphery that remains viable after treatment [15,16]. Thera-
peutic assessment based on biomarkers [27] directly or
indirectly related to their mechanism of action is therefore
necessary, as traditional measures of response alone may
not reflect their true biologic activity [16]. One such parameter
that has been used in the assessment of tumor response to
DMXAA in animal models and in patients is alteration in
vascular perfusion [28,29]. In this regard, contrast-enhanced
MRI has become an increasingly popular tool to monitor
vascular function following treatment [28,30]. The non-
invasive nature of MR, combined with its ability to sample
the whole tumor, makes it ideal for monitoring the effect of
vascular-targeted therapies [30]. Most contrast-enhanced
MRI studies performed to date have used low-molecular-
weight contrast agents that freely diffuse transendothelially
and have a high first-pass extraction fraction to evaluate
the response of tumors to antivascular treatments [30]. How-
ever, it is well-recognized that these low-molecular-weight
contrast agents may not be particularly well suited for this
purpose, as VDAs such as DMXAA are known to increase
vascular permeability and result in reduction of tumor blood
flow [16,31]. To avoid some of these complexities associated
with pharmacokinetic modeling and MR data interpretation,
Figure 3. Change in vascular volume and permeability following DMXAA.
Graph shows change in T1 relaxation rates (DR1) over time of untreated control
tumors (squares) and tumors treated with 30 mg/kg DMXAA (circles) for FaDu
(left panel) and A253 (right panel) xenografts. Vascular volume and
permeability values were calculated from DR1 using linear regression analysis.
Significant differences were seen between the vascular volumes (Y-intercepts)
of control FaDu and control A253 xenografts (P < .0001). Twenty-four hours
after treatment, only FaDu tumors exhibited a significant reduction in vascular
volume versus control (P < .0001). Analysis of the slopes of the plots also
revealed a significant difference in permeability between control and DMXAA-
treated FaDu tumors (P < .001).
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we have used a well-characterized intravascular agent
albumin-GdDTPA to obtain quantitative estimates of vascu-
lar perfusion in the two HNSCC xenografts 24 hours after
DMXAA treatment.
Previously, using contrast-enhanced MRI based on a
macromolecular contrast agent that remained predomi-
nantly intravascular in untreated tumors, we have shown
that DMXAA resulted in a significant increase in vascular
Figure 4. Effect of DMXAA therapy on HNSCC xenografts. Photomicrographs of control and DMXAA-treated FaDu (upper two rows) and A253 (lower two rows)
xenografts are shown before and 24 hours after DMXAA treatment. The left column shows H&E–stained tumor sections (original magnification, 200), and the
right column shows CD31-immunostained tumor sections (original magnification, 400). Control FaDu xenografts consist of uniformly poorly differentiated re-
gions (panel A) with increased MVD (panel B; arrows), whereas A253 tumors consist of hypoxic, avascular, well-differentiated islands (panel E) with fewer vessels
(panel F; arrows). Twenty-four hours after DMXAA treatment, both FaDu (panel C) and A253 (panel G) tumors showed extensive necrosis and loss of CD31
staining (FaDu, panel D; A253, panel H) indicative of significant DMXAA-induced vascular damage (arrows).
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permeability 4 hours after treatment in murine colon
26 tumors [24]. In the same study, in addition to an increase
in permeability 4 hours after treatment, we also observed a
significant reduction in R1 values 24 hours after DMXAA
treatment, indicative of significant alterations in vascular
perfusion at this time. We therefore chose to examine vas-
cular perfusion 24 hours after DMXAA treatment in the two
HNSCC xenografts. We hypothesized that if DMXAA
exhibited antivascular activity in the two xenografts, then
vascular shutdown induced by the drug 24 hours after treat-
ment would result in a decreased uptake of the contrast agent
and therefore a decrease in the MR parameter (DR1) mea-
sured. Changes in longitudinal relaxation rate [DR1 (R1 = 1 /
T1)] following administration of a contrast agent were eval-
uated before and 24 hours after treatment with DMXAA to
provide quantitative measures of tumor vascular volume
and permeability.
Our results show that DMXAA exhibits moderate antivas-
cular and antitumor activity against both HNSCC xenografts
used. MRI revealed significant vascular differences between
untreated FaDu and A253 tumors (Figures 1 and 2), in agree-
ment with our previous study [17]. Following DMXAA treat-
ment, FaDu tumors exhibited a more dramatic reduction in
vascular perfusion compared to A253 xenografts (Figures 2
and 3). This could be due to differences in the underlying his-
tologic structures of these xenografts. FaDu tumors consist
of uniformly poorly differentiated regions with higher MVD,
Figure 5. Estimates of MVD in FaDu and A253 xenografts following DMXAA
treatment. Bar graphs show MVD counts for control and DMXAA-treated
FaDu and A253 tumors per HPF (original magnification, 400). Significant
reduction in MVD was seen 24 hours after DMXAA treatment (two-tailed
Student’s t test, **P < .01, *P < .05).
Figure 6. Visualization of FaDu and A253 vascular response to DMXAA. T1 relaxation maps (lower panel) of a nude mouse bearing bilateral FaDu (yellow arrows)
and A253 (white arrows) xenografts. Maps (B) and (D) represent the precontrast and postcontrast images acquired before DMXAA treatment. Maps (F) and (H)
represent the precontrast and postcontrast images acquired 24 hours after DMXAA treatment. Twenty-four hours after DMXAA treatment, no detectable MR signal
enhancement was seen in FaDu tumors after contrast agent administration (map H) compared to precontrast images (map F). At the same time point, A253
showed enhancement, indicating the presence of functional vessels (maps F and H). Representative proton images are also shown (images A, C, E, and G).
Figure 7. Tumor growth inhibition following DMXAA. Nude mice bearing
bilateral FaDu and A253 xenografts were injected with 30 mg/kg DMXAA, and
tumor growth was monitored for a period of 30 days. Figure shows change in
median tumor volume between DMXAA-treated tumors and untreated
controls. DMXAA resulted in significant inhibition (P < .001) of the growth
of both xenografts compared to untreated controls.
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whereas A253 tumors consist of 30% well-differentiated
avascular regions and 70% poorly differentiated regions with
low MVD [17]. The tight cellular architecture of A253 tumors
is also believed to hinder endothelial cell penetration and
thereby prevent blood vessel formation [17]. This may have
contributed to the differential response of the two xeno-
grafts, as vascular endothelial cells are the primary targets
of VDAs, including DMXAA. Immunohistochemical staining
(Figure 4) and MVD counts (Figure 5) correlated with MR
findings and confirmed DMXAA-induced vascular damage.
Differences in the vascular response between the two tu-
mors were also visualized using contrast-enhanced MRI
(Figure 6). Contrast-enhanced MRI also demonstrated the
selectivity of antivascular effects of DMXAA, as normal
muscles and kidney tissues did not show any significant
change following treatment.
As summarized in Table 1, the histologic and vascular
characteristics of the two HNSCC xenografts used were
significantly different. Changes in MR parameters of vascular
function were predictive of the long-term outcome observed
following treatment. Although the vascular response to
DMXAA was more dramatic in FaDu tumors compared to
A253, tumor response studies demonstrated that DMXAA
resulted in significant growth inhibition of both tumors com-
pared to untreated controls (Figure 7). The observed dif-
ferences in the degree of vascular response to DMXAA
between the two tumors could have been a direct conse-
quence of differences in their vascularity. Nevertheless, the
moderate reduction in vascular perfusion seen in A253
following DMXAA treatment was still sufficient to produce a
significant antitumor effect. Because A253 tumors are less
vascularized to begin with, it could be that each vessel within
the tumor supports many more tumor cells compared to
FaDu tumors. Therefore, it is possible that the amount of
tumor cell kill achieved by DMXAA-induced vascular damage
is the same in A253 tumors as in FaDu tumors, accounting for
the same CR rates (20%) in both tumor types (Table 1).
The CR rates (20%) seen in these xenografts are not
completely surprising as VDAs such as DMXAA are not ex-
pected to cause significant growth delays as single agents
[31]. The true clinical usefulness of agents such as DMXAA is
believed to be in combination settings. Several preclinical
studies have shown significant synergistic activity of DMXAA
in combination with chemotherapy, radiation, and approaches
such as hyperthermia and gene therapy [31]. We have pre-
viously shown that administration of a low ineffective dose of
DMXAA significantly potentiates the antitumor activity and
selectivity of photodynamic therapy [24, 26].
Here, we have demonstrated the potential for the clinical
application of DMXAA in head and neck cancers. As such,
clinical trials employing VDAs such as CA4P, in combination
with radiotherapeutic and chemotherapeutic agents, are un-
derway for the management of thyroid cancer (http://www.
clinicatrials.gov; NCT00077103 and NCT00060242). Al-
though the activity of vascular-targeting agents such as
ZD6126 has been reported against HNSCC xenografts [32],
to the best of our knowledge, no preclinical studies evaluat-
ing the effect of DMXAA against head and neck tumors have
been published before this report. Taken together, DMXAA
appears to be moderately effective against HNSCC and may
be clinically useful in the management of head and neck
cancers, either alone or in combination. However, it is im-
portant to keep in mind that these studies were carried out
using implanted subcutaneous tumors and that the observed
antivascular and antitumor effects of DMXAA may be reflec-
tive of the response of tumors beneath the skin rather than
of orthotopic tumors. Systematic evaluation of the antitumor
effects of DMXAA using orthotopic tumor models is there-
fore necessary to better understand its clinical potential.
Studies aimed at addressing this issue are currently under-
way in our laboratory.
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